676496

VEGF Inhibitor, CBO-P11

The VEGF Inhibitor, CBO-P11 controls the biological activity of VEGF. This small molecule/inhibitor is primarily used for Phosphorylation & Dephosphorylation applications.

• Synonyme(s) : VEGF Inhibitor, CBO-P11, Cyclo-VEGI, cyclic( D-F-PQIMRIKPHQGQHIGE), D-Phe-Pro(79-93), VEGFR Tyrosine Kinase Inhibitor XX, VEGFR2 Kinase Inhibitor XVI, Cyclo-VEGI, cyclic(D-F-PQIMRIKPHQGQHIGE), D-Phe-Pro(79-93), VEGFR Tyrosine Kinase Inhibitor XX, VEGFR2 Kinase Inhibitor XVI
• Formule empirique (notation de Hill) : C₉₀H₁₄₀N₂₈O₂₂S
• Poids moléculaire : 1998.31
• NACRES: NA.77
• UNSPSC Code: 12352200
• Assay: ≥97% (HPLC)
• Form: lyophilized solid
• Storage condition: OK to freeze, desiccated (hygroscopic), protect from light

Propriétés

• Quality Segment: 100
• assay: ≥97% (HPLC)
• form: lyophilized solid
• manufacturer/tradename: Calbiochem^®
• storage condition: OK to freeze, desiccated (hygroscopic), protect from light
• color: white
• solubility: DMSO: 5 mg/mL, water: soluble
• shipped in: wet ice
• storage temp.: −20°C

Description

General description

A macrocyclic 17-amino acid peptide derived from residues 79 - 93 of vascular endothelial growth factor that mediate its binding to VEGFR-2. It blocks the binding of VEGF₁₆₅ to its receptors (IC₅₀ = 700 nM for VEGFR1, 1.3 µM for VEGFR2) and exhibits anti-angiogenic activity as well as other VEGFR-mediated cellular functions, such as proliferation (IC₅₀ = 5.8 µM), migration (IC₅₀ = 8.2 µM), and activation of MAP kinases. Its anti-angiogenic activity has been successfully demonstrated in vivo using chick embryos and nude mice tumor models of human intracranial and syngeneic glioma.

A macrocyclic, 17-amino acid peptide derived from residues 79-93 of vascular endothelial growth factor (VEGF) that mediates the binding of VEGF to its receptor, VEGFR-2. Blocks the binding of VEGF₁₆₅ to its receptors (IC₅₀ = 70 nM for VEGFR-1, 1.3 µM for VEGFR-2) and exhibits anti-angiogenic properties. Also reported to block other VEGF-mediated cellular functions such as proliferation (IC₅₀ = 5.8 µM), migration (IC₅₀ = 8.2 µM), and activation of MAP kinases. Also reported to exhibit anti-angiogenic properties in vivo using chick embryo and nude mouse tumor models of human intracranial and syngeneic glioma.

Biochem/physiol Actions

Cell permeable: no

Primary Target
Blocks the binding of VEGF165 to its receptors

Product does not compete with ATP.

Reversible: no

Target IC₅₀: 700 nM for VEGFR1, 1.3 µM for VEGFR2

Packaging

Packaged under inert gas

Physical form

Supplied as a trifluoroacetate salt.

Preparation Note

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.

Other Notes

Zilberberg, L., et al. 2003. J. Biol. Chem.278, 35564.

cyclic(D-Phe-Pro-Gln-Ile-Met-Arg-Ile-Lys-Pro-His-Gln-Gly-Gln-His-Ile-Gly-Glu)

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Disclaimer

Toxicity: Carcinogenic / Teratogenic (D)

Informations sur la sécurité

• Classe de stockage: 11 - Combustible Solids
• wgk: WGK 1
• flash_point_f: Not applicable
• flash_point_c: Not applicable